Skip to main content
Top
Published in: Familial Cancer 4/2009

01-12-2009

Cancer risk in a cohort of subjects carrying a single mismatch repair gene mutation

Authors: D. A. Stupart, P. A. Goldberg, U. Algar, R. Ramesar

Published in: Familial Cancer | Issue 4/2009

Login to get access

Abstract

Hereditary non-polyposis colon cancer (HNPCC) is an autosomal dominant condition, caused by germline mutations in the mismatch repair genes, that presents with colorectal cancers at a young age, as well as extracolonic tumours. One of the causative mutations is the C1528T (Exon 13) mutation of the MLH1 gene. The purpose of this study is to document the cancer risk for subjects who carry this mutation. This is a prospective cohort study of 200 subjects who carry this mutation. We calculated the risk of developing colorectal cancer only in those subjects who had not undergone surveillance colonoscopy. The incidence of extracolonic cancers (for which surveillance is not routinely offered) was determined for the entire cohort. The results of the study are among the 71 subjects who did not undergo surveillance colonoscopy, colorectal cancers occurred in 36 (51%). They occurred at a median age of 44 years (range 17–73). Using Kaplan–Meier estimates, the risk of developing a colorectal cancer by age 65 was 92%. Eighteen subjects in the cohort of 200 were diagnosed with extracolonic tumours. The most common extracolonic malignancies were breast (6/98 women) and endometrial (3/98 women). Thus this mutation has a high penetrance for colorectal cancer, but is not associated with a high risk of developing extracolonic malignancies.
Literature
1.
2.
go back to reference Ramesar RS, Madden MV, Felix R, Harocopos CJ, Westbrook CA, Jones G, Cruse JP, Goldberg PA (2000) Molecular genetics improves the management of hereditary non-polyposis colorectal cancer. S Afr Med J 90(7):709–714PubMed Ramesar RS, Madden MV, Felix R, Harocopos CJ, Westbrook CA, Jones G, Cruse JP, Goldberg PA (2000) Molecular genetics improves the management of hereditary non-polyposis colorectal cancer. S Afr Med J 90(7):709–714PubMed
3.
go back to reference Goldberg PA, Madden MV, Harocopos C, Felix R, Westbrook C, Ramesar RS (1998) In a resource-poor country, mutation identification has the potential to reduce the cost of family management for hereditary nonpolyposis colorectal cancer. Dis Colon Rectum 41(10):1250–1253CrossRefPubMed Goldberg PA, Madden MV, Harocopos C, Felix R, Westbrook C, Ramesar RS (1998) In a resource-poor country, mutation identification has the potential to reduce the cost of family management for hereditary nonpolyposis colorectal cancer. Dis Colon Rectum 41(10):1250–1253CrossRefPubMed
4.
go back to reference Anderson DW, Goldberg PA, Algar U, Felix R, Ramesar RS (2007) Mobile colonoscopic surveillance provides quality care for hereditary nonpolyposis colorectal carcinoma families in South Africa. Colorectal Dis 9(6):509–514CrossRefPubMed Anderson DW, Goldberg PA, Algar U, Felix R, Ramesar RS (2007) Mobile colonoscopic surveillance provides quality care for hereditary nonpolyposis colorectal carcinoma families in South Africa. Colorectal Dis 9(6):509–514CrossRefPubMed
5.
go back to reference Aarnio M, Mecklin JP, Aaltonen LA, Nyström-Lahti M, Järvinen HJ (1995) Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 64(6):430–433CrossRefPubMed Aarnio M, Mecklin JP, Aaltonen LA, Nyström-Lahti M, Järvinen HJ (1995) Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 64(6):430–433CrossRefPubMed
6.
go back to reference Vasen HF, Wijnen JT, Menko FH, Kleibeuker JH, Taal BG, Griffioen G, Nagengast FM, Meijers-Heijboer EH, Bertario L, Varesco L, Bisgaard ML, Mohr J, Fodde R, Khan PM (1996) Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110(4):1020–1027CrossRefPubMed Vasen HF, Wijnen JT, Menko FH, Kleibeuker JH, Taal BG, Griffioen G, Nagengast FM, Meijers-Heijboer EH, Bertario L, Varesco L, Bisgaard ML, Mohr J, Fodde R, Khan PM (1996) Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110(4):1020–1027CrossRefPubMed
7.
go back to reference Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, Burn J, Liu B, Kinzler KW, Vogelstein B (1997) Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 6(1):105–110CrossRefPubMed Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, Burn J, Liu B, Kinzler KW, Vogelstein B (1997) Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 6(1):105–110CrossRefPubMed
8.
go back to reference Jäger AC, Bisgaard ML, Myrhøj T, Bernstein I, Rehfeld JF, Nielsen FC (1997) Reduced frequency of extracolonic cancers in hereditary nonpolyposis colorectal cancer families with monoallelic hMLH1 expression. Am J Hum Genet 61(1):129–138CrossRefPubMed Jäger AC, Bisgaard ML, Myrhøj T, Bernstein I, Rehfeld JF, Nielsen FC (1997) Reduced frequency of extracolonic cancers in hereditary nonpolyposis colorectal cancer families with monoallelic hMLH1 expression. Am J Hum Genet 61(1):129–138CrossRefPubMed
9.
go back to reference Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, Peltomäki P, Mecklin JP, Järvinen HJ (1999) Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81(2):214–218CrossRefPubMed Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, Peltomäki P, Mecklin JP, Järvinen HJ (1999) Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81(2):214–218CrossRefPubMed
10.
go back to reference Vasen HF, Stormorken A, Menko FH, Nagengast FM, Kleibeuker JH, Griffioen G, Taal BG, Moller P, Wijnen JT (2001) MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 19(20):4074–4080PubMed Vasen HF, Stormorken A, Menko FH, Nagengast FM, Kleibeuker JH, Griffioen G, Taal BG, Moller P, Wijnen JT (2001) MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 19(20):4074–4080PubMed
11.
go back to reference Parc Y, Boisson C, Thomas G, Olschwang SJ (2003) Cancer risk in 348 French MSH2 or MLH1 gene carriers. Med Genet 40(3):208–213CrossRef Parc Y, Boisson C, Thomas G, Olschwang SJ (2003) Cancer risk in 348 French MSH2 or MLH1 gene carriers. Med Genet 40(3):208–213CrossRef
12.
go back to reference Barrow E, Robinson L, Alduaij W, Shenton A, Clancy T, Lalloo F, Hill J, Evans DG (2009) Cumulative lifetime incidence of extracolonic cancers in Lynch Syndrome: a report of 121 families with proven mutations. Clin Genet 75:141–149CrossRefPubMed Barrow E, Robinson L, Alduaij W, Shenton A, Clancy T, Lalloo F, Hill J, Evans DG (2009) Cumulative lifetime incidence of extracolonic cancers in Lynch Syndrome: a report of 121 families with proven mutations. Clin Genet 75:141–149CrossRefPubMed
13.
go back to reference Stupart DA, Goldberg PA, Algar U, Ramesar R (2009) Surveillance colonoscopy improves survival in a cohort of subjects with a single mismatch repair gene mutation. Colorectal Dis 11(2):126–130CrossRefPubMed Stupart DA, Goldberg PA, Algar U, Ramesar R (2009) Surveillance colonoscopy improves survival in a cohort of subjects with a single mismatch repair gene mutation. Colorectal Dis 11(2):126–130CrossRefPubMed
14.
go back to reference Quehenberger F, Vasen HF, van Houwelingen HC (2005) Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J Med Genet 42(6):491–496CrossRefPubMed Quehenberger F, Vasen HF, van Houwelingen HC (2005) Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J Med Genet 42(6):491–496CrossRefPubMed
15.
go back to reference Watson P, Lynch HT (2001) Cancer risk in mismatch repair gene mutation carriers. Fam Cancer 1(1):57–60CrossRefPubMed Watson P, Lynch HT (2001) Cancer risk in mismatch repair gene mutation carriers. Fam Cancer 1(1):57–60CrossRefPubMed
16.
go back to reference Lynch HT, Lynch J (2000) Lynch syndrome: genetics, natural history, genetic counseling, and prevention. J Clin Oncol 18(21 suppl):19S–31SPubMed Lynch HT, Lynch J (2000) Lynch syndrome: genetics, natural history, genetic counseling, and prevention. J Clin Oncol 18(21 suppl):19S–31SPubMed
17.
go back to reference Mitchell RJ, Farrington SM, Dunlop MG, Campbell H (2002) Mismatch repair genes hMLH1 and hMSH2 and colorectal cancer: a HuGEreview. Am J Epidemiol 156(10):885–902CrossRefPubMed Mitchell RJ, Farrington SM, Dunlop MG, Campbell H (2002) Mismatch repair genes hMLH1 and hMSH2 and colorectal cancer: a HuGEreview. Am J Epidemiol 156(10):885–902CrossRefPubMed
18.
go back to reference Vasen HF, Möslein G, Alonso A, Bernstein I, Bertario L, Blanco I, Burn J, Capella G, Engel C, Frayling I, Friedl W, Hes FJ, Hodgson S, Mecklin JP, Møller P, Nagengast F, Parc Y, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Wijnen J (2007) Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 44(6):353–362CrossRefPubMed Vasen HF, Möslein G, Alonso A, Bernstein I, Bertario L, Blanco I, Burn J, Capella G, Engel C, Frayling I, Friedl W, Hes FJ, Hodgson S, Mecklin JP, Møller P, Nagengast F, Parc Y, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Wijnen J (2007) Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 44(6):353–362CrossRefPubMed
19.
go back to reference Renkonen-Sinisalo L, Bützow R, Leminen A, Lehtovirta P, Mecklin JP, Järvinen HJ (2007) Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer 120(4):821–824CrossRefPubMed Renkonen-Sinisalo L, Bützow R, Leminen A, Lehtovirta P, Mecklin JP, Järvinen HJ (2007) Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer 120(4):821–824CrossRefPubMed
20.
go back to reference Dove-Edwin I, Boks D, Goff S, Kenter GG, Carpenter R, Vasen HF, Thomas HJ (2002) The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer 94(6):1708–1712CrossRefPubMed Dove-Edwin I, Boks D, Goff S, Kenter GG, Carpenter R, Vasen HF, Thomas HJ (2002) The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer 94(6):1708–1712CrossRefPubMed
21.
go back to reference Boilesen AE, Bisgaard ML, Bernstein I (2008) Risk of gynecologic cancers in Danish hereditary non-polyposis colorectal cancer families. Acta Obstet Gynecol Scand 87(11):1129–1135CrossRefPubMed Boilesen AE, Bisgaard ML, Bernstein I (2008) Risk of gynecologic cancers in Danish hereditary non-polyposis colorectal cancer families. Acta Obstet Gynecol Scand 87(11):1129–1135CrossRefPubMed
22.
go back to reference Blokhuis MM, Goldberg PA, Pietersen GE, Algar U, Vorster AA, Govender D, Ramesar RS (2008) The extracolonic cancer spectrum in females with the common ‘South African’ hMLH1 c. C1528T mutation. Fam Cancer 7(3):191–198 (Epub 2007)CrossRefPubMed Blokhuis MM, Goldberg PA, Pietersen GE, Algar U, Vorster AA, Govender D, Ramesar RS (2008) The extracolonic cancer spectrum in females with the common ‘South African’ hMLH1 c. C1528T mutation. Fam Cancer 7(3):191–198 (Epub 2007)CrossRefPubMed
Metadata
Title
Cancer risk in a cohort of subjects carrying a single mismatch repair gene mutation
Authors
D. A. Stupart
P. A. Goldberg
U. Algar
R. Ramesar
Publication date
01-12-2009
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 4/2009
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-009-9281-5

Other articles of this Issue 4/2009

Familial Cancer 4/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine